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Abstract:  
Renal cell carcinoma (RCC) has an undisputed genetic component and a stable 2:1 male to 
female sex ratio in its incidence across populations, suggesting possible sexual dimorphism in 
its genetic susceptibility. We conducted the first sex-specific genome-wide association analysis 
of RCC for men (3,227 cases, 4,916 controls) and  women (1,992 cases, 3,095 controls) of 
European ancestry from two RCC genome-wide scans and replicated the top findings using an 
additional series of  men (2,261 cases, 5,852 controls) and  women (1,399 cases, 1,575 controls) 
from two independent cohorts of European origin. Our study confirmed sex-specific 
associations for two known RCC risk loci at 14q24.2 (DPF3) and 2p21(EPAS1) and identified 
two additional suggestive male-specific loci at 6q24.3 (SAMD5, male odds ratio (ORmale)= 
0.83[95% CI=0.78-0.89], Pmale=1.71x10
-8  
compared with female odds ratio (ORfemale) = 0.98 
[95% CI=0.90-1.07], Pfemale=0.68) and 12q23.3 (intergenic, ORmale= 0.75[95% CI=0.68-0.83], 
Pmale =1.59 x10
-8
 compared with  ORfemale =0.93[95% CI=0.82-1.06], Pfemale=0.21) that attained 
genome-wide significance in the joint meta-analysis, but did not clearly replicate. Herein, we 
provide evidence of sex-specific associations in RCC genetic susceptibility and advocate the 
necessity of studies with greater statistical power to confirm the findings. 
 
 
 
 
 
 
 
 
Introduction 
Kidney cancer is the 12
th
 most common malignancy in the world with estimated 337,860 
new cases and 143,406 deaths in 2012 [1]. Renal cell carcinoma (RCC) accounts for 
approximately 90% of all kidney cancers [2].  The incidence differs significantly by sex, with 
two-fold higher rates for men than women. The 2:1 sex ratio has been consistent over time, 
across different age groups and geographical locations; and, hence, cannot be explained by 
differences in environmental or lifestyle exposures and hormonal factors alone [3]. Although 
there is recent evidence of sexual dimorphism at the genomic level, sex chromosome 
differences have gained most attention [4]. The first comprehensive sex-specific somatic 
alteration analysis of 13 cancer types from The Cancer Genome Atlas (TCGA) revealed 
extensive sex differences in autosomal gene expression and methylation signatures of kidney 
cancer, although it did not consider germline variation between sexes [5]. A genetic 
contribution to RCC susceptibility is well documented. Besides the rare inherited germline 
mutations implicated in some familial RCCs, e.g., VHL (von Hippel-Lindau disease), MET 
(hereditary papillary renal cancer), FLCN (Birt-Hogg-Dubé syndrome) and FH (hereditary 
leiomyomatosis and renal cell cancer) genes [6], large genome-wide association studies 
(GWAS) have identified 13 autosomal RCC susceptibility loci implicating several candidate 
genes [7-11]. A role for sex in modifying genetic susceptibility to RCC is possible, but, unlike 
many other sexually dimorphic diseases and traits [12-14], no genome-wide, systematic effort to 
study possible sex specific genetic contributions to kidney cancer risk has been undertaken. 
 We conducted a sex-specific genome wide association analysis of kidney GWAS 
datasets consisting of 13,230 individuals (8193 men, 5087 women) using approximately 6 
million genotyped and imputed SNPs in sex-stratified and sex interaction models and replicated 
the top findings using another 8,113 men and 2,974 women. To explore the possibility of sex-
specific gene regulation of the top genotypic variants, we performed an expression quantitative 
trait loci (eQTL) analysis using paired genotyping and gene expression data from normal and 
kidney tumour tissues.  
Methods 
Genetic association analysis 
Discovery  
The International Agency for Research on Cancer (IARC) kidney cancer GWAS have 
been previously described [11]. The dataset consisted of two IARC-Centre National de 
Genotypage (CNG) scans using 11 studies recruited from 18 countries and included a total of 
5,219 RCC cases (1,992 women, 3,227 men) and 8,011 controls (3,095 women, 4,916 men) of 
European descent, the first being genotyped using HumanHap 317k, 550 or 610Q, and the 
second using Omni5 and OmniExpress arrays. Quality control assessments applied to the data 
have been previously described [7, 11]. Briefly, we used the following quality control measures 
at individual levels as exclusion criteria, genotype success rate of <95%, discordant sex, 
duplication or relatedness based on IBD score >0.185 and samples with < 80% European 
ancestry. SNP exclusion criteria included call rate <90%, departure from Hardy Weinberg 
equilibrium in controls at P<10
-7
, and MAF<0.05. Imputation of genotypes was done by 
minimac version 3 using 1,094 subjects from the 1000 Genomes Project (phase 1 release 3) as 
the reference panel and approximately 6 million SNPs were retained for the final analysis after 
post imputational QC steps (r
2
>0.3). Population stratification analysis (implemented in 
EIGENSTRAT software) on the pooled dataset identified 19 significant (P<0.05) eigenvectors, 
showing significant association with the country of recruitment. Informed consent from the 
study participants and approval from the IARC Institutional Review Board (IARC Ethics 
Committee) was obtained. 
 
SNP selection 
Sexually dimorphic SNPs could have (i) a concordant effect direction (CED), if the 
association is present (i.e., significant after multiple testing correction) for one sex and 
nominally significant and directionally concordant for the other, (ii) single sex effect (SSE), if 
the association is present for one sex only, or (iii) opposite effect direction (OED), if the 
association is present for one sex, at least nominally significant and in opposite direction for the 
other sex [15]. Previous studies on sex-specific genetic associations indicated that sex-specific 
scans had a higher probability to select SNPs with CED or SSE signal, while sex-interaction 
scans had a higher probability to select SNPs with OED [15]. Therefore, in the discovery phase, 
we conducted both sex stratified and sex interaction scans. For the sex-stratified analysis, a log-
additive model using unconditional logistic regression adjusted for age, study and the 
significant eigenvectors were used to identify associations. For the sex interaction analysis, a 
regression model including the main effects of the genotypes, sex, covariates and an interaction 
term for genotypes and sex was used to detect association. We applied a false-discovery-rate 
(FDR) approach separately for male and female datasets to account for multiple testing and the 
difference in sample size. FDR q-value cut offs of 5% and 30% were used to detect significant 
and suggestive SNPs respectively in each of the datasets.  Accordingly, p-value threshold of 
1x10-6 and 4x10-6 was considered to be significant (5% FDR) and p-value threshold of 1.1x10-
5 and 5x10-5 was considered suggestive (30% FDR) for female and male datasets respectively. 
In addition to the significant and suggestive sex-specific p-values, a nominally significant 
(P<0.05) sex interaction p-value was taken into account in order to identify SNPs showing sex 
difference. The same FDR cut-offs were used to detect significant and suggestive signals in 
interaction tests (Supplementary figure S1). In addition, a clear LD cluster for the SNP was also 
considered as a criterion to avoid false positives. Among multiple SNPs in LD (r
2
 > 0.8, with 
LD-window of 1Mb) showing an association, we choose the one with the lowest missing rate 
and p-value. 
Replication and joint meta-analysis 
Replication of the top hits from the discovery phase was conducted using 3,660 cases 
(1,399 women, 2,261 men) and 7427 controls (1,575 women, 5,852 men) from two previously 
published National Cancer Institute (NCI, Bethesda, Maryland, USA) and one MD Anderson 
Cancer Center (MDA, Texas, USA) kidney GWAS scans genotyped using HumanHap 550, 610 
and 660W beadchip arrays. Quality control and genotype imputation was done as described 
previously [7, 8, 11]. For each study, sex-stratified and sex-interaction models for all significant 
and suggestive SNPs were tested assuming a log-additive model of genetic effects using 
unconditional logistic regression with adjustment for age, study centre, and significant 
eigenvectors. The odds ratios and 95% confidence intervals per SNP from each study were 
meta-analysed using fixed-effect models implemented in GWAMA [16], to get the combined 
estimates from the replication series.  We also performed a joined meta-analysis of results from 
the discovery and replication series to get the combined effect estimates of the tested SNPs. 
Heterogeneity in genetic effects across datasets was assessed using the I2 and Cochran’s Q 
statistics. 
Expression QTL analysis of the selected SNPs 
To identify gene regulatory effects of the identified SNPs, we examined transcript 
expression near each of the SNPs in 279 normal and 574 tumour kidney tissues separately for 
men and women. Expression analysis was conducted using Illumina HumanHT-12 v4 
expression BeadChips (Illumina, Inc., San Diego), normalised using variance stabilizing 
transformation (VST) and quantile normalization. Additive linear models were used to test the 
association between each transcript and SNP with age, country, tumour stage and grade as 
covariates. All transcripts within a 1 Mb upstream and downstream range of the SNPs were 
evaluated, and FDR adjusted p-value <0.05 using Benjamini-Hochberg procedure was used as 
statistical significance threshold. All probes with SNPs were filtered out. 
Results 
In the discovery phase, logistic regression testing separately for male and female 
datasets showed an excess of p-values less than 0.05 (Figure 1). The association Q-Q plots 
indicated little inflation for both the datasets (λfemale=1.02, λmale=1.04; supplementary figure S2a, 
b). A total of 17 SNPs (6 significant and 11 suggestive) were selected for follow-up; of which 
15 SNPs (5 significant and 10 suggestive) gave single sex-specific signals (SSE) and 2 SNPs 
namely, rs4903064 and rs6554676 (showing CED) were strongly associated in women and 
nominally in men (Supplementary table1). Among the 15 single sex-specific signals, 4 out of 
the 5 significant SNPs were male-specific, whereas, 7 of the 10 suggestive SNPs were female-
specific. Also, 7 were associated with an increased RCC risk in women and 3 in men, whereas, 
4 SNPs were associated with a decreased risk in men and 1 in women (Supplementary table 2). 
The strongest association was observed for rs4903064 in females (ORfemale= 1.47 [95% 
CI=1.33-1.62], Pfemale=9x10
-14
 compared with ORmale= 1.09 [95% CI= 1.01-1.19], Pmale= 0.02; 
Pinteraction=1.7x10
-5
) at 14q24.2 mapping to an intronic region of DPF3 (Figure 2). Other 
significant SNPs in discovery series, rs2121266 at 2p21, rs12930199 at 16p13.3 and rs1548141 
at 3q11.2 mapped to the intronic regions of EPAS1, RBFOX1 and OR5H6, respectively. 
Significant SNPs rs10484683 and rs78971134 mapped to intergenic regions at 7p22.3 and 
6q24.3, with the nearest genes being BTBD11 and SAMD5, respectively. For rs78971134 
(SAMD5) the minor allele frequencies were similar for male and female cases. Regional LD 
plots for each of the loci are detailed in Supplementary Figure S3 (a) and (b).  In contrast, the 
sex-interaction scan did not identify any SNP even at 30% FDR and no SNP could be carried 
forward (Supplementary figure 4a,b). 
Sex-stratified analysis of the 17 SNPs in the replication phase exhibited stronger effect 
for DPF3 in women compared with men (ORfemale=1.24 [95%CI= 1.07-1.42], Pfemale=3x10
-3
   
compared with ORmale= 1.09 [0.98-1.21], Pmale=0.09).  In   addition rs147304092 (BBS9), 
rs13027293 (STEAP3) rs6554676 (SLC6A18) showed nominally significant association with 
RCC risk for either men or women in the follow-up series (Table 1). No other SNP exhibited 
any significant sex difference in the replication series.  
We performed a joint meta-analysis of the discovery and replication series (8,061 
women and 16,256 men) for the selected 17 SNPs. In addition to the consistent findings for 
DPF3 (metaORfemale=1.38, metaPfemale=1.54 x 10
-14
 compared with metaORmale=1.09, 
metaPmeta=0.005; metaPinteraction = 0.002), we found a stronger association for males for EPAS1 
(metaORmale=1.18, metaPmale=1.84 x 10
-09
 compared with metaORfemale=1.09, metaPfemale= 0.02; 
metaPinteraction =0.03) but with significant study heterogeneity in the female dataset.  Two 
additional SNPs reached genome-wide significance in the joint meta-analysis.Both rs10484683 
at SAMD5 (metaORfemale=0.98, metaPfemale=0.68 compared with metaORmale=0.83, 
metaPmeta=1.71x10
-08
,metaPinteraction=0.10) and rs78971134 near BTBD11(metaORfemale=0.93, 
metaPfemale=0.26, compared with metaORmale=0.75, metaPmeta=1.59x10
-08
; metaPinteraction= 0.14) 
showed an inverse association with risk for men but not women (Table 1). The results of 
replication and final meta-analysis of all the 17 SNPs are listed in supplementary table 2. 
We also examined sex-specific expression of genes corresponding to the selected SNPs 
using Illumina expression data in normal and tumour kidney tissues. Although no gene with 
significant sex-difference in expression was detected in normal tissues, we observed a higher 
expression of SAMD5 in tumour tissues of women (Supplementary table 3). We further tested 
the effect of the identified SNPs on expression of nearby genes by detecting cis expression 
quantitative trait loci (eQTL) in kidney tissues. No significant eQTL was identified for any of 
the 17 SNPs in normal tissues, but we identified rs4903064 as a significant eQTL for DPF3 
expression in tumours (P=1.88 x 10
-8
). We further examined sex-specific cis-eQTLs and found 
a stronger association of rs4903064 on DPF3 for women compared with men (βwomen=0.06, 
Pwomen=2.69 x 10
-6
 vs βmen=0.03, Pmen=0.004, Psex_interaction=0.03 Figure 3). A borderline 
association was also observed for rs6554676 and SLC6A18 expression in male tumour tissues 
only (βmale=-0.21, Pmale=0.05 vs βfemale=-0.01, Pfemale=0.94).  
Discussion 
We conducted the first systematic sex-specific genome-wide association analysis of 
RCC and observed sexually dimorphic associations for two previously known risk SNPs on 
DPF3 and EPAS1 at 14q24 and 2p21, respectively. In a joint meta-analysis of top hits using 
8,061 women and 16,256 men, we also identified two additional suggestive SNPs (rs10484683 
at SAMD5 and rs78971134 near BTBD11) with possible sex-specific associations – both being 
associated with a lower risk for men, and with no strong evidence of association for women. 
We report a higher risk of RCC for women for rs4903064 at DPF3 gene and also 
provide evidence that the association might be mediated through expression of the gene, with 
the magnitude of the association between the SNP and expression being greater for women than 
men. rs4903064 was previously reported to be associated with increased RCC risk in a large 
GWAS [11], and our analysis confirms the previous reports of its sex-specific association. 
Polymorphisms at intron 1 of DPF3 are also associated with increased risk of breast cancer for 
women of European origin, but the SNPs were not in linkage disequilibrium with rs4903064 
[17].  DPF3 is a histone acetylation and methylation reader of the BAF and PBAF chromatin 
remodeling complexes. Other components of the complexes like BAP1 and PBRM1 are 
frequently mutated in RCC and show sex differences in their mutation frequency and 
association with survival [18]. Chromatin-remodeling complexes regulate gene expression and 
loss of these chromatin modifiers has been associated with characteristic gene expression 
signatures in RCC [19, 20]. Sexually dimorphic gene expression is frequent in both murine [21] 
and human [5, 22] kidney normal and tumour tissues, and is hypothesized to contribute to the 
mechanism underlying sex-difference in kidney diseases including cancer [4, 23]. Therefore, 
polymorphisms and mutations of chromatin remodeling complex associated genes might modify 
RCC risk differently for men and women through sex-specific gene expression but the exact 
mechanism remains speculative and requires detailed functional studies in vitro. 
The SNP rs2121266 mapping to intron 1 of the EPAS1 gene is in strong linkage 
disequilibrium (r
2=0.97, D’=1.00) to the previously described risk SNP rs11894252 at 2p21[7]. 
We report a sex-specific association of this variant showing stronger association for men in the 
discovery set. This is in agreement with previous findings of stronger associations for the proxy 
SNP rs11894252 for men (ORmale=1.18 compared with ORfemale=1.06, Pinteraction=0.03) in RCC. 
Additionally, sexually dimorphic associations for EPAS1 variants were also observed for 
rs13419896 in lung squamous cell carcinoma [24] and rs4953354 in lung adenocarcinoma [25] 
in two independent reports from a Japanese population. EPAS1 (HIF2α) is a key gene in RCC 
and functions as a transcription factor in the VHL–HIF signalling axis [26, 27]. The intron 1 of 
EPAS1 contains estrogen response elements (EREs) and estrogen-dependent downregulation of 
EPAS1 occurs in invasive breast cancer cells [28]. RCC related polymorphisms near other 
important genes like CCND1, MYC/PVT1 have been found on enhancers at tissue-specific HIF-
binding loci in renal tubular cells [29, 30], implying a role for HIF in transactivation of key 
oncogenic pathways in RCC. Although rs2121266 and rs11894252 were not eQTLs for EPAS1, 
it is possible that the role of these polymorphisms in sex hormone mediated regulation of 
EPAS1 and transactivation of downstream genes may result in sex-specific susceptibility to 
RCC. 
 Two other SNPs that reached genome-wide significance in the joint analysis of 
discovery and replication series, namely rs10484683 at SAMD5 and rs78971134 near BTBD11 
have not been previously reported to be associated with risk of RCC. For rs10484683 (SAMD5), 
the sex-specific finding from the discovery stage was driven by MAF differences in the controls 
only. Hence, the result remains unclear and might be the reason that the apparent association did 
not replicate. The SNP rs10484683 was not a significant cis eQTL in normal or tumour kidney 
tissues in our series, but expression of SAMD5 varied significantly between tumour samples 
from men and women. Although not implicated in RCC, SAMD5 overexpression has been 
found to be associated with bile duct and cholangiocarcinoma [31]. BTBD11 gene codes for an 
ankyrin repeat and BTB/POZ domain-containing protein involved in regulation of proteolysis 
and protein ubiquitination. Functional implications of this gene is not well known in RCC, but 
SNPs near the BTBD11 gene were previously reported to be associated with kidney function 
traits[32] and diabetic kidney diseases[33] by large genome-wide studies.  
In the discovery series, we observed that rs147304092 at 7p14.3, mapping to an intronic region 
of the BBS9 gene, was associated with substantially lower risk for women but not men.  BBS9 is 
implicated in Bardet-Biedl Syndrome (BBS), a rare autosomal recessive ciliopathy with a wide 
spectrum of clinical features including obesity, renal abnormalities, mental retardation, 
hypogonadism etc. [34]. This gene is also a candidate tumour suppressor gene in Wilms’ 
tumour, the most common paediatric malignancy of the kidney [35]. Nevertheless, this 
observation was not replicated and did not reach genome-wide significance in the meta-
analysis; fine mapping of this locus in larger studies might identify new global or sex-specific 
candidates of RCC.    
We confirmed sex specific genetic associations of known RCC risk SNPs and identified 
new suggestive associations for one or the other sex, but without clear replication. Also, no 
clear pattern of an increased risk for men or decreased risk for women could be observed in the 
top sexually dimorphic SNPs, as would be otherwise anticipated for explaining the 2:1 sex 
ratios. Therefore, these SNPs are not conclusive for untangling the sex-specific genetic 
susceptibility that might contribute to the sex ratio in incidence. Due to technical constraints we 
could not examine sex chromosomal associations in the current study. Even given its large 
sample size, a drawback of the study is its limited statistical power to detect subtle sex-specific 
associations, particularly when analysing men and women separately. A male-specific 
association may simply reflect the lack of power to detect association in women, owing to the 
smaller sample size for women compared with men. To increase the power to detect sex-
specific associations, the combination of results from different GWAS in sex-stratified meta-
analyses is warranted. Therefore, considering sex-specific scans and sex chromosomes in 
performing genome-wide association studies will also provide an opportunity to examine sex 
associations in addition to overall associations in sexually dimorphic diseases and traits.  
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Legends to Figures: 
Figure 1. Sex stratified genome-wide association scan in renal cell carcinoma: Manhattan 
plots of male and female specific association P-values from the discovery series. 
Figure 2.Regional plot of the most significant sex-specific loci: P-values and LD among SNPs 
at 14q24.2 mapping to the DPF3 gene in women and men. 
Figure 3. cis-eQTL: boxplot displaying expression levels of DPF3 gene stratified by the risk 
SNP rs4903064 in women and male kidney tumour tissues. 
 
